Tuesday, 17 Sep 2019

You are here

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The long-term objectives in managing AS are to improve quality of life, prevent structural damage, and preserve function. Deodhar and colleagues sought to analyze the efficacy of TNFi as measured by persistence, discontinuations, and switching over 2 years of follow up.

This retrospective analysis of adult AS patient data was gathered from the IBM MarketScan Commercial Claims database, specifically looking at patients initiating a TNFi from 01/01/2009 to 12/31/2013. AS patients with other inflammatory diagnoses were excluded. Discontinuation was defined as a ≥ 90-day gap in therapy without starting a new TNFi.  Persistence was defined a no gaps in therapy (≥ 90 days) during the 2-year follow-up.

Analysis of 1372 AS patients (846 males/526 females) found that the most common TNFi started was adalimumab (~44%), followed by etanercept (~41%), infliximab (~10%), golimumab (~4%), and certolizumab (<1%).  The main points of the study included: 

  • Over 2 years only 33% of AS patients (n = 454) persisted on their index TNFi
  • 41% discontinued their index TNFi and did not restart a TNFi
  • 26% stopped their index TNFi and switched to a second TNFi
  • Patients also taking cDMARDs were more likely to persist with their index TNFi  
  • Less likely to persist were females and opioid users 

These retrospective results suggest a higher than expected discontinuation and switching rate amongst AS patients starting a TNFi. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).